ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1500

Investigating Serum Lipids Classifying Psoriatic Arthritis Disease Activity Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry
Abstract Number: 1002

Investigation of Pharmacodynamic Biomarkers in a Phase 2b Study in Patients with Moderate to Severe SLE Treated with the S1P1 Receptor Modulator Cenerimod
Abstract Number: 0876

Investigation of Predictive Factors for Active Disease Status Within 24 Months of Juvenile Idiopathic Arthritis Diagnosis
Abstract Number: PP04

Invisible to Invincible: The Role of Virtual Events in Autoimmune Advocacy, Education and Community Building
Abstract Number: 1550

Involvement of Iliofemoral Arteries in PET/CT Are Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis
Abstract Number: 0255

Is Abatacept as Effective and Safe in Rheumatoid Arthritis Patients with Previous Malignancy as in Those Without?
Abstract Number: 1994

Is Glucocorticoid Bridging Associated with Later Glucocorticoid and Biological DMARD Use in Patients with Rheumatoid Arthritis?
Abstract Number: 1503

Is Inflammation-driven Bone Loss Associated with Two-year Bone Formation at the Same Vertebra in Axial Spondyloarthritis? – a Multilevel MRI and Low Dose CT Analysis from the Sensitive Imaging of Axial Spondyloarthritis (SIAS) Cohort
Abstract Number: 1544

Is It Possible to Evaluate Polymyalgia Rheumatica Without C-reactive Protein? Concordance and Agreement Between Different PMR Activity Scores in Polymyalgia Rheumatica
Abstract Number: 1480

Is Lupus Podocytopathy a New Variant of Lupus Nephritis?
Abstract Number: 1345

Is Perceived Stress Associated with COVID-19 or Having a Systemic Rheumatic Disease?
Abstract Number: 1014

Is Radiographic Axial Involvement Associated with Syndesmophyte Development After 2 Years in PsA Patients?
Abstract Number: 0141

Is Rituximab Associated with Worse Outcomes in COVID-19 Patients? A Meta-analysis
Abstract Number: 0838

Is SARS-CoV-2 Associated with Worse Outcomes After Total Knee Arthroplasty?
Abstract Number: 0197

Is Similar the Same? How We Incorporated Feedback from 250 Patients into a CME Activity on Biosimilars

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].